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THE COST OF DIABETES RELATED MINOR HYPOGLYCEMIC EVENTS IN 
WORKING ADULTS
Brod M1, Christensen TE2, Thomsen TL2, Bushnell D3
1The BROD GROUP, Mill Valley, CA, USA, 2Novo Nordisk A/S, Virum, Denmark, 3Health 
Research Associates, Inc, Mountlake Terrace, WA, USA
OBJECTIVES: Diabetes-related minor hypoglycemic episodes (MHEs) have been 
found to be signiﬁcantly related to decreased treatment satisfaction. Unfortunately 
little is known regarding the impact of MHEs on work productivity and costs for 
people who work. METHODS: A US web-based survey of persons with diabetes was 
conducted. RESULTS: 6,756 persons with diabetes were surveyed. Of these 830 had 
at least one MHE in the past month, of whom 411 indicated working for pay, which 
is the population used for this analysis. Of the 411, 200 (48.7%) respondents had 
type 1 and 211 (51.3%) had type 2 diabetes. 290 (70.6%) were taking insulin and 
121 (29.4%) used only oral hypoglycemic agents. The mean age was 49.5 o 13.2, 
64.0% were females and average duration of diabetes was 15.8 o 12.7 years. 385 
(94%) reported MHEs, either at work or during sleep which affected their work, in 
the past year. For their latest MHE at work, the average amount of time respondents 
reported not functioning at their usual work productivity level (presenteeism) was 9.1 
hours. 34 subjects reported 1.0 days of absence from work after a MHE at the work 
place (e.g. leaving early or missing meetings). Additionally, 31 respondents had MHE 
during the night which resulted in 1.7 days of absence the following days. On average, 
these respondents used 6.9 extra blood sugar monitoring tests per MHE and $66.25 
out-of-pocket was spent on foods, glucose products, changes in transportation, etc. in 
the past month due to MHEs. CONCLUSIONS: It appears that lost productivity 
(presenteeism and absenteeism) and the costs of MHEs have been underestimated and 
should be considered an important part of diabetes management. Treatments which 
reduce MHEs would increase work productivity and decrease cost of care.
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USING FACTOR ANALYSIS TO CONFIRM THE VALIDITY OF DIABETES 
HEALTH PROFILE-1, DIABETES AND LIFE STYLE FOR TURKISH 
DIABETIC PATIENTS
Malhan S1, Oksuz E1, Baytar S2, Tulunay FC3
1Baskent University, Ankara, Turkey, 2Baskent University, ankara, Turkey, 3Ankara University 
Medical School, Ankara, Turkey
OBJECTIVES: As in most countries, Diabetes Mellitus is a disease causing signiﬁcant 
burden to Turkey. The treatments and their beneﬁts affect not only the patient, but 
their friends, families and other relationships as well. Therefore, feedback regarding 
the quality of life of a Diabetes Mellitus patient is meaningful. The aim of this study 
was to determine the reliability and validity of the Diabetes Health Proﬁle-1 (DHP-1) 
for Turkish Diabetic patients. METHODS: The scale, which was translated into 
Turkish from English, again translated back into English by 2 independent translators, 
was applied to 45 diabetic patients for pre-test. After assessment of the results, the 
questionnaire was applied to 60 diabetic patients. Cronbach’s Alfa was used to assess 
reliability and factor analysis to assess dimensionality. The EuroQol-5D was used for 
concurrent validity. RESULTS: The internal consistency coefﬁcient (Cronbach’s alpha) 
of DHP-1was 0.86. Factor analysis of the scale revealed that it was composed of ﬁve 
factors with Eigenvalues 1, accounting for 74.4% of the total variance. All items of 
the Turkish DHP had a factor load ranging from 0.578 to 0.838. CONCLUSIONS: 
The DHP-1 has good validity and reliability for Turkish Diabetic patients.
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PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS 
TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS 
GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-
COM STUDY
Moock J1, Hessel F2, Kohlmann T1
1University of Greifswald, Greifswald, Germany, 2Sanoﬁ-Aventis, Berlin, Germany
OBJECTIVES: Although basal insulins glargine (GLA) or detemir (DET) appear to 
have similar clinical efﬁcacy for treatment of type 2 diabetes (T2D), there are several 
differences between these two regimens that could affect outcomes from a patient’s 
perspective. The purpose of this study was to compare treatment experiences (TE) and 
treatment satisfaction (TS) associated with insulin administration in T2D patients 
treated with either GLA or DET in a basal-bolus regimen for at least 6 months. 
METHODS: LIVE-COM (Long Acting Insulin Glargine versus Insulin Detemir Cost 
Comparison in Germany) was a non-interventional, cross-sectional, retrospective 
study performed between April and September 2008 in 138 randomly selected centers 
of primary care physicians in Germany. The study enrolled 1731 T2D patients with 
statutory health insurance status eligible for documentation when either treated with 
GLA (n  1150) or DET (n  581) as part of a basal-bolus regimen for at least 6 
months prior to documentation. Patients completed the Insulin Treatment Experience 
Questionnaire (ITEQ), a new condition-speciﬁc instrument assessing TE and TS, and 
the Diabetes Treatment Satisfaction Questionnaire (DTSQs). To examine differences   
between the two treatment group’s independent t-test and general linear models 
(GLMs) were used. RESULTS: Treatment experiences and satisfaction analyses were 
conducted with data from 1,718 per protocol patients (GLA: 1,141; DET: 577). ITEQ 
subscales (sleep, diabetes control, weight control), ITEQ total score differed between 
insulin groups and were clearly better (p  0.05) in GLA group (ITEQ total score: 
68.6 o 12.7 vs. 66.7 o 13.9, p  0.004). Differences in DTSQs total score failed to     
reach statistical signiﬁcance (28.8 o 5.9 vs. 28.2 o 5.8, p  0.064) Results of the GLMs 
indicate that differences between the insulin groups were stable after adjustment. 
CONCLUSIONS: Under real life conditions, our results indicate that glargine was 
associated with signiﬁcant higher treatment experiences as well as treatment satisfac-
tion compared to detemir among T2D patients treated in a basal-bolus regimen.
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COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 
DIABETES (T2DM): EFFECTS ON WORK PRODUCTIVITY
Purayidathil FW, Gupta S, Wagner S
Consumer Health Sciences International (a KantarHealth Company), Princeton, NJ, USA
OBJECTIVES: To evaluate the impact of comorbid depression in patients with T2DM 
on work productivity and activity impairment in France, Germany Italy, Spain and 
the UK. METHODS: Data were from the 2008 U.S. National Health and Wellness 
Survey (NHWS), an annual cross-sectional survey of self-reported health care behav-
iors, disease states, and outcomes of adults aged 18, translated for each country. A 
cohort of patients with T2DM without comorbid depression was compared to a 
cohort of T2DM with comorbid depression. Depression was deﬁned as afﬁrmative 
responses in the past month to: bothered by feeling down, depressed or hopeless; and 
bothered by having little interest or pleasure in doing things. The Work Productivity 
and Activity Impairment (WPAI) questionnaire measured productivity; regression 
models adjusted for gender, age, country, marital status, education and an adjusted 
Charlson Comorbidity Index score. RESULTS: Among 2668 respondents diagnosed 
with T2DM, 828 (31%) were female and 750 (28%) experienced symptoms of depres-
sion. Of 873 employed patients, 275 had symptoms of depression. After controlling 
for our covariates, employed patients with comorbid depression had signiﬁcantly 
worse levels of absenteeism [B  11.15, t  5.66; p  0.001] and impairment while at 
work (presenteeism) [B  20.96, t  11.72; p  0.001], and had signiﬁcantly more 
overall work loss [B  25.58, t  11.59; p  0.001]. For all respondents activity impair-
ment was also signiﬁcantly higher for patients with comorbid depression [B  22.76, 
t  21.40; p  0.001]. Germany has a greater amount of presenteeism, and work pro-
ductivity loss (p  0.05) than the other EU countries compared to the UK in this study; 
however, France, Germany, Italy and Spain patients experience signiﬁcantly less activ-
ity impairment than UK patients (p  0.05). CONCLUSIONS: Patients with T2DM 
and comorbid depression reported signiﬁcantly more absenteeism and presenteeism 
overall. Treating both diseases effectively might lessen burden of disease and related 
indirect costs; further research is needed to clarify geographical and cultural inﬂuence 
associated with lost productivity.
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ASSESSING THE BURDEN OF ACROMEGALY: A REVIEW OF HEALTH-
RELATED QUALITY OF LIFE AND ECONOMICS
Stephens JM1, Gao X2, Pulgar S3, Sheppard MC4
1PharMerit North America LLC, Bethesda, MD, USA, 2Pharmerit North America LLC, 
Bethesda, MD, USA, 3Novartis Pharmaceuticals, Florham Park, NJ, USA, 4The University of 
Birmingham, Birmingham, UK
OBJECTIVES: Treatment goals for acromegaly, an endocrine disorder characterized 
by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1), have 
centered around biochemical control. The objective of this study is to describe the 
health-related quality of life (HRQoL) burden and economic impact of acromegaly. 
METHODS: A review of the literature from the past 12 years was conducted using 
MEDLINE, Econlit, and EMBASE using QoL, economics, costs, and utility as search 
terms. Additional searches were conducted from article bibliographies and conference 
proceedings. Selected articles were speciﬁcally designed to examine HRQoL or direct 
medical costs associated with acromegaly in adults. RESULTS: Of 97 abstracts identi-
ﬁed, 57 (22 HRQoL, 37 economic) met selection criteria. HRQoL has been assessed 
for acromegaly using 15 distinct instruments. Patients with acromegaly consistently 
reported lower HRQoL than population-based controls. Acromegaly patients have 
HRQoL scores similar to HIV patients, and signiﬁcantly lower than patients with 
arthritis, chronic lung disease, diabetes and hypertension. Some studies showed that 
HRQoL improved with biochemical control, but results were not consistent. For the 
economic burden, the average direct medical costs per patient varied from $4,000 to 
$28,000 annually. Costs in the ﬁrst year after diagnosis were approximately 2–3x 
higher than other years. Estimated annual costs of care prior to diagnosis were roughly 
equivalent to annual costs after diagnosis. Lifetime costs exceeded $1,000,000 per 
patient. Key cost drivers were comorbidities, treatment strategy, and response to 
treatment. Patients not achieving biochemical control had total medical costs 1.6 times 
higher than those who were controlled. CONCLUSIONS: There is a substantial 
HRQoL and economic burden for acromegaly. Treatment and optimization of bio-
chemical control may lead to improvements in QoL and reductions in direct medical 
costs. Future areas of research should include a holistic evaluation of both costs and 
HRQoL on clinical consequences of alternative treatment strategies for acromegaly.
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LINGUISTIC VALIDATION, INCLUDING CULTURAL ADAPTATION, OF 
AN UPDATED ADKNOWL, DIABETES KNOWLEDGE QUESTIONNAIRE, 
FOR INTERNATIONAL USE
Celerier S1, Plowright R2, Reaney M3, Bradley C2
1MAPI Institute, Lyon, France, 2University of London, Egham, UK, 3Eli Lilly, Windlesham, UK
OBJECTIVES: Linguistic validation of a diabetes knowledge questionnaire that is 
internationally acceptable and detects common misunderstandings and important 
educational needs. A rigorous methodology was employed to ensure conceptual 
equivalence and cultural relevance as well as harmonisation across countries. 
METHODS: The Audit for Diabetes Knowledge (ADKnowl) (104 Items in 23 sections) 
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was developed in UK English (Speight and Bradley; 2001) and most recently updated 
in 2008 in consultation with UK diabetologists, a diabetes specialist nurse (DSN), a 
dietician, and a podiatrist. A conceptual deﬁnition of each item was provided by the 
developer, forward translations were produced in Germany and Spain. Results of the 
ﬁrst translations and questions were discussed with the developer and a diabetologist, 
DSN, dietician and the translation team in each country. The initial UK version was 
revised. The German and Spanish versions were back translated into UK English and 
tested for acceptability and comprehension during cognitive debrieﬁng interviews with 
eight people with diabetes in each country, before ﬁnal language versions were estab-
lished. RESULTS: First results obtained after the forward translation and discussion 
in Spain and Germany showed that diabetes management differs somewhat across 
countries and differences in dietary habits and alcohol use necessitated some adapta-
tion to the questions. The establishment of a harmonized questionnaire required some 
rewording of items and reordering. Challenges encountered, including those concern-
ing diet and alcohol, and how these were dealt with during all steps of the process 
will be described in the presentation. CONCLUSIONS: An internationally acceptable 
version of the ADKnowl was developed following a rigorous methodology to facilitate 
international comparison and pooling of data. This project demonstrates the impor-
tance of assessing the suitability of the item content of a knowledge measure to the 
clinical and cultural context of the target countries.
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THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN 
DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT 
SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES 
INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING 
DRUGS (OGLDS)
Swinnen SG1, Hajos T2, Holleman F1, Dain MP3, DeVries JH1, Hoekstra JB1, Snoek FJ2
1Academic Medical Centre, Amsterdam, The Netherlands, 2VU University Medical Centre, 
Amsterdam, The Netherlands, 3Sanoﬁ-aventis, Paris , France
OBJECTIVES: To compare the impact of starting either insulin glargine once-daily 
or insulin detemir twice-daily on multiple dimensions of QOL in patients with type 
2 diabetes inadequately controlled on OGLDs. METHODS: This study was part of 
a 24-week, multinational, randomised trial in which 964 insulin-naïve patients, 
aged 40–75 years, with inadequately controlled type 2 diabetes (HbA1c 7.0–10.5%) 
were randomised to glargine once-daily or detemir twice-daily. For both insulins the 
dose was titrated every 2 days by 2 U to obtain fasting plasma glucose 5.6 mmol/l. 
For detemir, there also was a pre-dinner target 5.6 mmol/l. QOL and TS were 
assessed using: type 2 Diabetes Symptom Checklist revised (DSC-r), World Health 
Organization-5 well-being index (WHO-5), Hypoglycaemia Fear Survey (HFS) and 
Diabetes Treatment Satisfaction Questionnaire (DTSQ). Higher scores indicate greater 
symptom distress, well-being, worries about hypoglycaemia and TS, respectively. 
Data were analysed using ANCOVA. RESULTS: HbA1c reductions and overall 
hypoglycaemia were comparable between glargine and detemir (mean o SD change in 
HbA1c: 1.46 o 1.09 and 1.54 o 1.11%, respectively [P  0.149]). Total diabetes-
related symptom distress (DSC-r) decreased in both treatment groups. There were 
no signiﬁcant differences between groups, except for the neuropathic pain subscale 
(P  0.027 in favour of glargine). Well-being (WHO-5) increased equally in both 
groups (6.13 o 21.47 for glargine and 7.54 o 19.06 for detemir on scale 0–100, P 
 0.742). There was no signiﬁcant difference between treatments for the HFS (P  
0.441). TS (DTSQ) improved for both treatment groups, but signiﬁcantly more for 
glargine than for detemir: Mean o SD increase in total satisfaction score (scale 0–36): 
5.1 o 8.6 for glargine and 4.1 o 8.8 for detemir (P  0.001). CONCLUSIONS: Initiat-
ing glargine once-daily or detemir twice-daily in patients with type 2 diabetes failing 
OGLDs resulted in similarly improved glycaemic control, associated with an overall 
positive effect on diabetes symptom distress and emotional well-being. TS improved 
with both insulins, however, improvement was signiﬁcantly greater with glargine 
than detemir.
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COMPARING THE IMPACT OF DEPRESSION, DIABETES, AND ANXIETY 
ON PATIENT PRODUCTIVITY AND QUALITY OF LIFE: RESULTS FROM 
A NATIONALLY REPRESENTATIVE PANEL DATA
Bansal M1, Nair R1, Bollu V2
1St. John’s University, Queens, NY, USA, 2Novartis Oncology, East Hanover, NJ, USA
OBJECTIVES: This study aims to estimate and compare quality of life and productiv-
ity loss among three chronic and prevalent conditions. METHODS: Retrospective 
secondary database analysis using Medical Expenditure Panel Survey data from years 
2000–2003 was conducted. Patients identiﬁed using the 3-digit ICD-9 codes: diabe-
tes(250) depression(311) and anxiety(300). QOL was measured using EQ-5D & pro-
ductivity measured using absenteeism data. RESULTS: A total of 12,858 patients were 
identiﬁed, 11% of patients had two or more of the conditions studied. About 17% 
of diabetes patients had an EQ-5D index score of 0.30, compared to 20% each on 
depression and anxiety. All 3 conditions had signiﬁcant impact on patient’s overall 
QOL (p  0.001). Mean EQ 5D index for diabetes was 0.65 (95% CI 0.64–0.66), 
depression—0.62 (95% CI 0.61–0.63), and anxiety—0.62 (95% CI 0.61–0.64). More 
number of patients with depression and anxiety missed work (21%) and stayed in bed 
(17%) due to illness compared to diabetes patients (12% and 9% respectively), but 
the mean days diabetes patients missed work was higher—12.15 (95% CI 10.38–
13.92) compared to anxiety—9.39 (95% CI 7.8–10.89) and depression—8.88 (95% 
CI 7.79–9.96) CONCLUSIONS: All three conditions were found to have a signiﬁcant 
negative impact on patient’s QoL and productivity. Our research indicates that anxiety 
and depression inﬂict similar disease burden compared to diabetes on patient. Future 
research should focus on reducing this burden.
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THE “WHO, HOW AND THEN WHAT . . .” OF INSULIN INITIATION IN 
UK PRIMARY CARE
Smith HT1, Blak BT2, Hards M2, Arellano J1
1Eli Lilly and Company, Surrey, UK, 2CSD EPIC, London, UK
OBJECTIVES: To understand how insulin is initiated, describe patients with type 2 
diabetes (T2DM) initiating insulin in UK primary care, and look at changes in therapy, 
clinical outcomes and contact with health care professionals (HCPs) after insulin ini-
tiation. METHODS: Patients aged q18 years with a code for T2DM initiating insulin 
(baseline) from May 2004 to May 2006 were identiﬁed in the THIN database. Patient 
characteristics, clinical measures, treatment and contact with HCPs were collected at 
baseline and during 6 months follow-up. RESULTS: A total of 4045 patients met the 
inclusion criteria, 56% were male. Patient characteristics at baseline [mean (SD)] were; 
age: 62.6(13.3) years, BMI: 30.2(6.5) kg/m2 and HbA1c: 9.6%(2.0%). The most preva-
lent co-morbidities were hypertension (63%), coronary heart disease (26%), hyperli-
paedemia (24%), and depression (22%). 97.4% of patients had contact with their 
GP-surgery in the 6 months before insulin initiation, mean 7.1 contacts; 78.1% were 
referred to secondary care; and 18% were hospitalised. In the 12 months prior to 
insulin initiation 8.5% of patients had no prescriptions for oral antidiabetic medica-
tions (OAD), 13.4% for a single OAD class and 78.1% for q2 different OAD classes. 
52.4% of patients initiated intermediate/long acting insulin therapy only, a further 
41.6% pre-mix insulin only and the remainder initiated basal bolus (4.0%) or fast 
acting only (2.1%). During follow-up, 14.7% discontinued insulin therapy, 6.8% 
switched to a different regimen and 4.7% intensiﬁed therapy; adding mealtime insulin. 
Of the patients with a measurement during follow-up (n  3024), 17.3% achieved 
target HbA1c (7%). Clinical outcomes during follow-up [mean (SD)] were; HbA1c: 
8.3 (1.6)% and BMI: 30.7 (6.6) kg/m2. There was a slight increase in contact with 
HCPs during follow-up, mean 8.5 GP-surgery contacts. CONCLUSIONS: Patients 
had elevated HbA1c at insulin initiation, simple regimens were favoured; during a 
6 month follow-up a high proportion of patients failed to achieve glycaemic target.
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USING THE ECHO MODEL TO EXAMINE THE EFFECT OF AN 
EMPLOYER-SPONSORED PHARMACIST PROVIDED DIABETES MTM 
PROGRAM ON OUTCOMES
Pinto SL, Holl S
The University of Toledo, Toledo, OH, USA
OBJECTIVES: To examine economic, clinical, and humanistic outcomes of a pharma-
cist-provided Medication Therapy Management (MTM) program. METHODS: One 
year prospective, pre-post longitudinal study. Employees and dependents with a diag-
nosis of Type 2 diabetes were included. Pharmacists provided MTM services at 7 com-
munity pharmacies on ﬁve occasions in one year. Data collected: economic outcomes 
included costs and numbers of ER visits hospitalizations etc., clinical (A1C, blood 
pressure etc.), social (caffeine intake, alcohol consumption etc.), and process measures 
(podiatrist visits, eye exams, etc.), humanistic (patient’s quality of life (SF-36), medica-
tion adherence etc.). Data was analyzed using SPSS v. 16.0. Descriptive statistics, Wil-
coxon signed-rank tests and Friedman tests were used. Data analyses for the period 
between baseline and 6 month is given below. RESULTS: Ninety ﬁve patients enrolled 
at baseline. Mean A1c improved from 8.02 to 7.67 (p  0.20). Patients with uncon-
trolled A1cs at baseline saw a signiﬁcant decrease toward goal at six months. (p  0.01). 
Systolic blood pressure improved from 136.00 to 131.94 mmHg (p  0.221) and 
improved signiﬁcantly for patients with baseline SBP q 140 (p  0.000). Patients satis-
faction (p  0.000) and adherence improved from baseline (p  0.015). Quality of life 
scores improved but these changes were not signiﬁcant. Visits to specialty physicians 
improved signiﬁcantly from the previous year. On average, physician ofﬁce visits 
reduced from 10.2 to 8.36. Number and costs for ER visits decreased. Average hospi-
talization costs decreased from $ 22,252.24 to $ 17,016.19 and length of stay decreased 
by approximately 1.4 days. Total costs decreased by 62.69% (^$200,000). CONCLU-
SIONS: This MTM program has demonstrated improved outcomes and cost savings 
within the ﬁrst six months. Final results for the one year time point will be presented.
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EVALUATION OF THE PATIENT’S PERSPECTIVE OF MEDICAL CARE IN 
TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS
Stark R1, Holle R2, Schunk M3, Meisinger C3, Leidl R4
1Helmholtz Zentrum München, Neuherberg , Germany, 2Helmholtz Zentrum München, 
Neuherberg, Germany, 3Helmholtz Zentrum München, Neuherberg, Germany, 4Helmholtz 
Zentrum München—German Research Center for Environmental Health, Neuherberg (by 
Munich), Germany
OBJECTIVES: Diabetes disease management programmes (DDMP) were introduced 
in German statutory health insurance companies to improve medical care by funding 
health care based on evidence-based medical guidelines. The aim of this study was to 
compare persons with type 2 diabetes (DM2s) enrolled in a DDMP to those not 
enrolled regarding quality of health care and medical endpoints. METHODS: A popu-
lation based follow-up study was performed by the Cooperative Health Research in 
the Region of Augsburg (KORA) between 2006 and 2008. All DM2s received a 
